![Enrolling children with acute lymphoblastic leukaemia on a clinical trial improves event-free survival: a population-based study | British Journal of Cancer Enrolling children with acute lymphoblastic leukaemia on a clinical trial improves event-free survival: a population-based study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2017.462/MediaObjects/41416_2018_Article_BFbjc2017462_Fig1_HTML.jpg)
Enrolling children with acute lymphoblastic leukaemia on a clinical trial improves event-free survival: a population-based study | British Journal of Cancer
![Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation](https://www.astctjournal.org/cms/attachment/7b390ded-6c92-4578-8079-4e858709eaf2/ybbmt54468-fig-0001_lrg.jpg)
Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation
![Kaplan-Meier curve for overall survival (OS) and event-free survival (EFS) according to the expression of CD30 and treatment. Kaplan-Meier curve for overall survival (OS) and event-free survival (EFS) according to the expression of CD30 and treatment.](https://s3-eu-west-1.amazonaws.com/ppreviews-plos-725668748/2068158/preview.jpg)
Kaplan-Meier curve for overall survival (OS) and event-free survival (EFS) according to the expression of CD30 and treatment.
ASH 2022: FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3
![Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma | SpringerLink Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-020-04195-z/MediaObjects/277_2020_4195_Fig4_HTML.png)
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma | SpringerLink
![Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma](https://www.frontiersin.org/files/Articles/835389/fonc-12-835389-HTML/image_m/fonc-12-835389-g002.jpg)
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
![Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-67147-7/MediaObjects/41598_2020_67147_Fig1_HTML.png)
Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports
![A prognostic nomogram for event-free survival in patients with atrial fibrillation before cardiac resynchronization therapy | BMC Cardiovascular Disorders | Full Text A prognostic nomogram for event-free survival in patients with atrial fibrillation before cardiac resynchronization therapy | BMC Cardiovascular Disorders | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12872-020-01502-4/MediaObjects/12872_2020_1502_Fig1_HTML.png)
A prognostic nomogram for event-free survival in patients with atrial fibrillation before cardiac resynchronization therapy | BMC Cardiovascular Disorders | Full Text
Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI | Haematologica
![MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients](https://www.spandidos-publications.com/article_images/ol/24/4/ol-24-04-13450-g03.jpg)
MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients
![Six-Year Natural History Comparison with Mirum's LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome | Business Wire Six-Year Natural History Comparison with Mirum's LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome | Business Wire](https://mms.businesswire.com/media/20211115006047/en/927128/23/MRX_EFS_graph_FINAL_AASLD_2021.jpg)
Six-Year Natural History Comparison with Mirum's LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome | Business Wire
![A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine](https://www.thelancet.com/cms/attachment/8b10cd73-be2f-4363-ba25-eb395b6c06c4/gr2_lrg.jpg)
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
![A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine](https://www.thelancet.com/cms/attachment/42242196-7947-4953-8385-0cd868f209d3/gr1.jpg)
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
![Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2022/jco.2022.40.issue-8/jco.21.01548/20220227/images/keyimage.jpg)
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology
![OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURVIVAL | Annals of the Rheumatic Diseases OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURVIVAL | Annals of the Rheumatic Diseases](https://ard.bmj.com/content/annrheumdis/80/Suppl_1/180/F1.large.jpg)
OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURVIVAL | Annals of the Rheumatic Diseases
![Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic](https://d3i71xaburhd42.cloudfront.net/2aa8254fae649d2ab35d92abb79d94fa9d17f39e/4-Figure1-1.png)
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer | PLOS ONE
![Prognostic Index for Predicting Overall Survival and Event-Free Survival In Total Therapy 3 Patients - ScienceDirect Prognostic Index for Predicting Overall Survival and Event-Free Survival In Total Therapy 3 Patients - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497119434125-fx1.jpg)